Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 20/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29842732 | 1.00 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL20702876 | 1.00 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL29842844 | 1.00 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL20705328 | 0.89 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL29842868 | 0.89 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL20702807 | 0.87 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL30692586 | 0.87 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL20702904 | 0.87 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL22697068 | 0.86 | PDE3B (1.00) | PDE3BPDE3A | |
| SCHEMBL26364082 | 0.86 | PDE3B (1.00) | PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258323-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2025-03-25 | — | — | US | claimed |
| CN-111212647-B | Dihydro oxadiazinones | 拜耳股份有限公司 | 2024-05-14 | — | — | CN | claimed |
| EP-4301371-A1 | SUBSTITUTED 3,6-DIHYDRO-2H-1,3,4-OXADIAZIN-2-ONES FOR THE TREATMENT OF SARCOMA | Bayer Aktiengesellschaft (DE) | 2024-01-10 | — | — | EP | claimed |
| CN-117279644-A | Substituted 3, 6-dihydro-2H-1, 3, 4-oxadiazin-2-ones for the treatment of sarcomas | 拜耳股份有限公司 | 2023-12-22 | — | — | CN | claimed |
| US-20230405015-A1 | SUBSTITUTED 3,6-DIHYDRO-2H-1,3,4-OXADIAZIN-2-ONES FOR THE TREATMENT OF SARCOMA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-21 | — | — | US | claimed |
| EP-3661517-B1 | DIHYDROOXADIAZINONES | BAYER AG (DE) | 2023-09-13 | — | — | EP | claimed |
| US-20230017200-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-19 | — | — | US | claimed |
| WO-2022184748-A1 | SUBSTITUTED 3,6-DIHYDRO-2H-1,3,4-OXADIAZIN-2-ONES FOR THE TREATMENT OF SARCOMA | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-09 | — | — | WO | claimed |
| US-20200369633-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-26 | — | — | US | claimed |
| EP-3661517-A1 | DIHYDROOXADIAZINONES | Bayer Aktiengesellschaft (DE) | 2020-06-10 | — | — | EP | claimed |
| CN-111212647-A | Dihydroxadiazinones | 拜耳股份有限公司 | 2020-05-29 | — | — | CN | claimed |
| WO-2019025562-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | claimed |
| US-12258323-B2 | Dihydrooxadiazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2025-03-25 | — | — | US | disclosed |
| CN-111212647-B | Dihydro oxadiazinones | 拜耳股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4301371-A1 | SUBSTITUTED 3,6-DIHYDRO-2H-1,3,4-OXADIAZIN-2-ONES FOR THE TREATMENT OF SARCOMA | Bayer Aktiengesellschaft (DE) | 2024-01-10 | — | — | EP | disclosed |
| CN-117279644-A | Substituted 3, 6-dihydro-2H-1, 3, 4-oxadiazin-2-ones for the treatment of sarcomas | 拜耳股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-3661517-A1 | DIHYDROOXADIAZINONES | Bayer Aktiengesellschaft (DE) | 2020-06-10 | — | — | EP | disclosed |
| CN-111212647-A | Dihydroxadiazinones | 拜耳股份有限公司 | 2020-05-29 | — | — | CN | disclosed |
| WO-2019025562-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019025562-A1 | DIHYDROOXADIAZINONES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369633-A1 | DIHYDROOXADIAZINONES | CCND2, CCNT2, CCND1 | PDE3B 1101/4885PDE3A 1148/4885 |
| US-12258323-B2 | Dihydrooxadiazinones | CCND2, CCNT2, CCND1 | PDE3B 1101/4885PDE3A 1148/4885 |
| US-20230405015-A1 | SUBSTITUTED 3,6-DIHYDRO-2H-1,3,4-OXADIAZIN-2-ONES FOR THE TREATMENT OF SARCOMA | EWSR1, SDHA, IDH3B | PDE3B 1781/4885PDE3A 1719/4885 |
| US-20230017200-A1 | DIHYDROOXADIAZINONES | CCND2, CCNT2, CCND1 | PDE3B 1101/4885PDE3A 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.